Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71.
The company reported sales of $3.88 billion, up 3% year over year, beating the consensus of $3.79 billion.
Eylea Performance
In the quarter, U.S. net sales for Eylea HD and Eylea decreased 28% year-over-year to $1.08 billion, including $506 million from Eylea HD and $577 million from Eylea.
Eylea product sales were negatively impacted by lower sales volumes as a result of continued competitive pressures, loss in market share to compounded bevacizumab due to patient affordability constraints, and the continued transition of patients to Eylea HD, and a lower net selling price.
In November 2025, the U.S. Food and Drug Administration (FDA) approved Eylea HD (aflibercept) Injection 8 mg for